View in EDS PDF Full Text

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Saved in:
Bibliographic Details
Title: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Authors: Colhoun HM (AUTHOR), Betteridge DJ (AUTHOR), Durrington PN (AUTHOR), Hitman GA (AUTHOR), Neil HAW (AUTHOR), Livingstone SJ (AUTHOR), Thomason MJ (AUTHOR), Mackness MI (AUTHOR), Charlton-Menys V (AUTHOR), Fuller JH (AUTHOR), CARDS (Collaborative Atorvastatin Diabetes Study) Investigators (CORPORATE AUTHOR), Colhoun, Helen M (AUTHOR), Betteridge, D John (AUTHOR), Durrington, Paul N (AUTHOR), Hitman, Graham A (AUTHOR), Neil, H Andrew W (AUTHOR), Livingstone, Shona J (AUTHOR), Thomason, Margaret J (AUTHOR), Mackness, Michael I (AUTHOR), Charlton-Menys, Valentine (AUTHOR)
Source: Lancet. 8/21/2004, Vol. 364 Issue 9435, p685-696. 12p.
Abstract: Background: Type 2 diabetes is associated with a substantially increased risk of cardiovascular disease, but the role of lipid-lowering therapy with statins for the primary prevention of cardiovascular disease in diabetes is inadequately defined. We aimed to assess the effectiveness of atorvastatin 10 mg daily for primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-cholesterol.Methods: 2838 patients aged 40-75 years in 132 centres in the UK and Ireland were randomised to placebo (n=1410) or atorvastatin 10 mg daily (n=1428). Study entrants had no documented previous history of cardiovascular disease, an LDL-cholesterol concentration of 4.14 mmol/L or lower, a fasting triglyceride amount of 6.78 mmol/L or less, and at least one of the following: retinopathy, albuminuria, current smoking, or hypertension. The primary endpoint was time to first occurrence of the following: acute coronary heart disease events, coronary revascularisation, or stroke. Analysis was by intention to treat.Findings: The trial was terminated 2 years earlier than expected because the prespecified early stopping rule for efficacy had been met. Median duration of follow-up was 3.9 years (IQR 3.0-4.7). 127 patients allocated placebo (2.46 per 100 person-years at risk) and 83 allocated atorvastatin (1.54 per 100 person-years at risk) had at least one major cardiovascular event (rate reduction 37% [95% CI -52 to -17], p=0.001). Treatment would be expected to prevent at least 37 major vascular events per 1000 such people treated for 4 years. Assessed separately, acute coronary heart disease events were reduced by 36% (-55 to -9), coronary revascularisations by 31% (-59 to 16), and rate of stroke by 48% (-69 to -11). Atorvastatin reduced the death rate by 27% (-48 to 1, p=0.059). No excess of adverse events was noted in the atorvastatin group.Interpretation: Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular disease events, including stroke, in patients with type 2 diabetes without high LDL-cholesterol. No justification is available for having a particular threshold level of LDL-cholesterol as the sole arbiter of which patients with type 2 diabetes should receive statins. The debate about whether all people with this disorder warrant statin treatment should now focus on whether any patients are at sufficiently low risk for this treatment to be withheld. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 106673142
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Colhoun+HM%22">Colhoun HM</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Betteridge+DJ%22">Betteridge DJ</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Durrington+PN%22">Durrington PN</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hitman+GA%22">Hitman GA</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Neil+HAW%22">Neil HAW</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Livingstone+SJ%22">Livingstone SJ</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Thomason+MJ%22">Thomason MJ</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mackness+MI%22">Mackness MI</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Charlton-Menys+V%22">Charlton-Menys V</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fuller+JH%22">Fuller JH</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22CARDS+%28Collaborative+Atorvastatin+Diabetes+Study%29+Investigators%22">CARDS (Collaborative Atorvastatin Diabetes Study) Investigators</searchLink> (CORPORATE AUTHOR)<br /><searchLink fieldCode="AR" term="%22Colhoun%2C+Helen+M%22">Colhoun, Helen M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Betteridge%2C+D+John%22">Betteridge, D John</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Durrington%2C+Paul+N%22">Durrington, Paul N</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hitman%2C+Graham+A%22">Hitman, Graham A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Neil%2C+H+Andrew+W%22">Neil, H Andrew W</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Livingstone%2C+Shona+J%22">Livingstone, Shona J</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Thomason%2C+Margaret+J%22">Thomason, Margaret J</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mackness%2C+Michael+I%22">Mackness, Michael I</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Charlton-Menys%2C+Valentine%22">Charlton-Menys, Valentine</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 8/21/2004, Vol. 364 Issue 9435, p685-696. 12p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>Type 2 diabetes is associated with a substantially increased risk of cardiovascular disease, but the role of lipid-lowering therapy with statins for the primary prevention of cardiovascular disease in diabetes is inadequately defined. We aimed to assess the effectiveness of atorvastatin 10 mg daily for primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-cholesterol.<bold>Methods: </bold>2838 patients aged 40-75 years in 132 centres in the UK and Ireland were randomised to placebo (n=1410) or atorvastatin 10 mg daily (n=1428). Study entrants had no documented previous history of cardiovascular disease, an LDL-cholesterol concentration of 4.14 mmol/L or lower, a fasting triglyceride amount of 6.78 mmol/L or less, and at least one of the following: retinopathy, albuminuria, current smoking, or hypertension. The primary endpoint was time to first occurrence of the following: acute coronary heart disease events, coronary revascularisation, or stroke. Analysis was by intention to treat.<bold>Findings: </bold>The trial was terminated 2 years earlier than expected because the prespecified early stopping rule for efficacy had been met. Median duration of follow-up was 3.9 years (IQR 3.0-4.7). 127 patients allocated placebo (2.46 per 100 person-years at risk) and 83 allocated atorvastatin (1.54 per 100 person-years at risk) had at least one major cardiovascular event (rate reduction 37% [95% CI -52 to -17], p=0.001). Treatment would be expected to prevent at least 37 major vascular events per 1000 such people treated for 4 years. Assessed separately, acute coronary heart disease events were reduced by 36% (-55 to -9), coronary revascularisations by 31% (-59 to 16), and rate of stroke by 48% (-69 to -11). Atorvastatin reduced the death rate by 27% (-48 to 1, p=0.059). No excess of adverse events was noted in the atorvastatin group.<bold>Interpretation: </bold>Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular disease events, including stroke, in patients with type 2 diabetes without high LDL-cholesterol. No justification is available for having a particular threshold level of LDL-cholesterol as the sole arbiter of which patients with type 2 diabetes should receive statins. The debate about whether all people with this disorder warrant statin treatment should now focus on whether any patients are at sufficiently low risk for this treatment to be withheld. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=106673142
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/s0140-6736(04)16895-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 685
    Titles:
      – TitleFull: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Colhoun HM
      – PersonEntity:
          Name:
            NameFull: Betteridge DJ
      – PersonEntity:
          Name:
            NameFull: Durrington PN
      – PersonEntity:
          Name:
            NameFull: Hitman GA
      – PersonEntity:
          Name:
            NameFull: Neil HAW
      – PersonEntity:
          Name:
            NameFull: Livingstone SJ
      – PersonEntity:
          Name:
            NameFull: Thomason MJ
      – PersonEntity:
          Name:
            NameFull: Mackness MI
      – PersonEntity:
          Name:
            NameFull: Charlton-Menys V
      – PersonEntity:
          Name:
            NameFull: Fuller JH
      – PersonEntity:
          Name:
            NameFull: CARDS (Collaborative Atorvastatin Diabetes Study) Investigators
      – PersonEntity:
          Name:
            NameFull: Colhoun, Helen M
      – PersonEntity:
          Name:
            NameFull: Betteridge, D John
      – PersonEntity:
          Name:
            NameFull: Durrington, Paul N
      – PersonEntity:
          Name:
            NameFull: Hitman, Graham A
      – PersonEntity:
          Name:
            NameFull: Neil, H Andrew W
      – PersonEntity:
          Name:
            NameFull: Livingstone, Shona J
      – PersonEntity:
          Name:
            NameFull: Thomason, Margaret J
      – PersonEntity:
          Name:
            NameFull: Mackness, Michael I
      – PersonEntity:
          Name:
            NameFull: Charlton-Menys, Valentine
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 21
              M: 08
              Text: 8/21/2004
              Type: published
              Y: 2004
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 364
            – Type: issue
              Value: 9435
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1